Cue Biopharma is trading at $26.92, up 5.53%, with no confirmed explanation for the September 30, 2026 move. - No new company-specific announcement explaining the move surfaced in the available news search. - Positive CUE-221 Phase 2 results were announced September 20; they are prior context, not a confirmed catalyst for this rebound. - Broad indexes are higher, but supplied readings are modest and do not establish a clear cause for the stock-specific gain.